Reverse mutation of the virulence-associated S2 gene does not cause an attenuated equine infectious anemia virus strain to revert to pathogenicity

Virology

Volumn 443, Issue 2, 2013, Pages 321-328

  Gao, Xu ^a,b   Jiang, Cheng Gang ^a   Wang, Xue Feng ^a   Lin, Yue Zhi ^a   Ma, Jian ^a   Han, Xiu E ^a,c   Zhao, Li Ping ^a   Shen, Rong Xian ^a   Xiang, Wen Hua ^a   Zhou, Jian Hua ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b YANBIAN UNIVERSITY   (China)

^c NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

EIAV; Pathogenicity; Reverse mutation; S2

Indexed keywords

EQUINE INFECTIOUS ANEMIA VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DONKEY; EQUINE INFECTIOUS ANEMIA; EQUINE INFECTIOUS ANEMIA VIRUS; FETUS; HORSE; IMMUNOSUPPRESSIVE TREATMENT; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; REVERTANT; S2 GENE; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

EIAV; PATHOGENICITY; REVERSE MUTATION; S2;

AMINO ACID SEQUENCE; ANIMALS; EQUINE INFECTIOUS ANEMIA; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MOLECULAR SEQUENCE DATA; MUTATION; VACCINES, ATTENUATED; VIRAL LOAD; VIRAL PROTEINS; VIRAL VACCINES; VIRULENCE; VIRUS REPLICATION;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 84880508715     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.05.017     Document Type: Article

References (16)

1. Covaleda L., Gno B.T., Fuller F.J., Payne S.L. Identification of cellular proteins interacting with equine infectious anemia virus S2 protein. Virus Res. 2010.
2. Craigo J.K., Durkin S., Sturgeon T.J., Tagmyer T., Cook S.J., Issel C.J., Montelaro R.C. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 2007, 25(5):834-845.
3. Craigo J.K., Zhang B., Barnes S., Tagmyer T.L., Cook S.J., Issel C.J., Montelaro R.C. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc. Natl. Acad. Sci. USA 2007, 104(38):15105-15110.
4. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(5090):1938-1941.
5. Fagerness A.J., Flaherty M.T., Perry S.T., Jia B., Payne S.L., Fuller F.J. The S2 accessory gene of equine infectious anemia virus is essential for expression of disease in ponies. Virology 2006, 349(1):22-30.
6. Jiang C.G., Gao X., Ma J., Lin Y.Z., Wang X.F., Zhao L.P., Hua Y.P., Liu D., Zhou J.H. C-terminal truncation of the transmembrane protein of an attenuated lentiviral vaccine alters its in vitro but not in vivo replication and weakens its potential pathogenicity. Virus Res. 2011, 158(1-2):235-245.
7. Kestler H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65(4):651-662.
8. Leroux C., Cadore J.L., Montelaro R.C. Equine infectious anemia virus (EIAV): what has HIV's country cousin got to tell us?. Vet. Res. 2004, 35(4):485-512.
9. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., Montelaro R.C. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J. Virol. 2003, 77(13):7244-7253.
10. Lin Y.Z., Shen R.X., Zhu Z.Y., Deng X.L., Cao X.Z., Wang X.F., Ma J., Jiang C.G., Zhao L.P., Lv X.L., Shao Y.M., Zhou J.H. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern. Antiviral. Res. 2011, 92(2):292-304.
11. Ma J., Jiang C., Lin Y., Wang X., Zhao L., Xiang W., Shao Y., Shen R., Kong X., Zhou J. In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine. Arch. Virol. 2009, 154(5):867-873.
12. Payne S.L., Fuller F.J. Virulence determinants of equine infectious anemia virus. Curr. HIV Res. 2010, 8(1):66-72.
13. Qi X., Wang X., Wang S., Lin Y., Jiang C., Ma J., Zhao L., Lv X., Shen R., Wang F., Kong X., Su Z., Zhou J. Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13. Virus Genes 2010, 41(1):86-98.
14. Wang X., Wang S., Lin Y., Jiang C., Ma J., Zhao L., Lv X., Wang F., Shen R., Kong X., Zhou J. Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains. Arch. Virol. 2011, 156(2):353-357.
15. Whitney J.B., Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 2004, 17(1):17-26.
16. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 1999, 73(10):8356-8363.